• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

伴有H3K27M突变的弥漫性中线胶质瘤的形态学谱系及生存分析

Morphological Spectrum and Survival Analysis of Diffuse Midline Glioma With H3K27M Mutation.

作者信息

Hassan Usman, Latif Maliha, Yousaf Irfan, Bin Anees Saad, Mushtaq Sajid, Akhtar Noreen, Loya Asif

机构信息

Pathology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, PAK.

Histopathology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, PAK.

出版信息

Cureus. 2021 Aug 17;13(8):e17267. doi: 10.7759/cureus.17267. eCollection 2021 Aug.

DOI:10.7759/cureus.17267
PMID:34540489
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8448278/
Abstract

Background Diffuse midline gliomas with the H3K27M mutation are now recognized as separate entities due to their unique molecular signature, clinical features, and adverse outcome. Objective To determine the morphological spectrum and survival rate of diffuse midline gliomas with H3K27M mutation. Material and methods This retrospective study was conducted between January 2015 and January 2021 at Shaukat Khanum Memorial Cancer Hospital and Research Centre. Medical records of 28 cases of H3K27M-mutated midline gliomas were retrieved. Case slides were reviewed and the pertinent histological spectrum was evaluated. Results The mean age of patients was 24.36 ± 14.06 years. There were 21 (75%) males and 7 (25%) females. Biopsy was performed in 22 (78.6%), total resection in 1 (3.6%) while subtotal resection was done in 5 (17.9%) cases. Histologically, a spectrum of morphologies was noted with pilocytic astrocytoma (WHO grade 1) at one end and glioblastoma (WHO grade IV) at the other end. Immunohistochemically, all 28 cases were positive for Histone 3 immunohistochemistry. ATRX was performed in 7 (25.0%) cases with loss of ATRX expression in 3 (10.7%) and retained expression in 4 (14.3%) cases. Ki67 was <5% in 6 (21.4%), 5-10% in 1 (3.6%), 11-15% in 1 (3.6%), 16-20% in 3 (10.7%), 21-25% in 4 (14.3%), and 26-30% in 2 (7.1%) cases. The mean survival was 8.00 ± 9.39 months. Out of 28 patients, 15 (62.5%) patients died of disease. Conclusion Diffuse midline gliomas with H3K27M mutation is an aggressive entity with a broad morphological spectrum.

摘要

背景

具有H3K27M突变的弥漫性中线胶质瘤因其独特的分子特征、临床特征和不良预后,现在被视为独立的实体。目的:确定具有H3K27M突变的弥漫性中线胶质瘤的形态学谱和生存率。材料与方法:本回顾性研究于2015年1月至2021年1月在沙卡特·汗姆纪念癌症医院和研究中心进行。检索了28例H3K27M突变的中线胶质瘤的病历。复查病例切片并评估相关的组织学谱。结果:患者的平均年龄为24.36±14.06岁。男性21例(75%),女性7例(25%)。22例(78.6%)进行了活检,1例(3.6%)进行了全切,5例(17.9%)进行了次全切。组织学上,观察到一系列形态,一端为毛细胞型星形细胞瘤(世界卫生组织1级),另一端为胶质母细胞瘤(世界卫生组织IV级)。免疫组化方面,28例均为组蛋白3免疫组化阳性。7例(25.0%)进行了ATRX检测,3例(10.7%)ATRX表达缺失,4例(14.3%)表达保留。Ki67<5%的有6例(21.4%),5 - 10%的有1例(3.6%),11 - 15%的有1例(3.6%),16 - 20%的有3例(10.7%),21 - 25%的有4例(14.3%),26 - 30%的有2例(7.1%)。平均生存期为8.00±9.39个月。28例患者中,15例(62.5%)死于疾病。结论:具有H3K27M突变的弥漫性中线胶质瘤是一种具有广泛形态学谱的侵袭性实体。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1298/8448278/bc3dde177797/cureus-0013-00000017267-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1298/8448278/381a89d6e967/cureus-0013-00000017267-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1298/8448278/84972b1bf35c/cureus-0013-00000017267-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1298/8448278/bc3dde177797/cureus-0013-00000017267-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1298/8448278/381a89d6e967/cureus-0013-00000017267-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1298/8448278/84972b1bf35c/cureus-0013-00000017267-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1298/8448278/bc3dde177797/cureus-0013-00000017267-i03.jpg

相似文献

1
Morphological Spectrum and Survival Analysis of Diffuse Midline Glioma With H3K27M Mutation.伴有H3K27M突变的弥漫性中线胶质瘤的形态学谱系及生存分析
Cureus. 2021 Aug 17;13(8):e17267. doi: 10.7759/cureus.17267. eCollection 2021 Aug.
2
[Clinicopathological characteristics and prognosis of diffuse midline gliomas with histone H3K27M mutation: an analysis of 30 cases].组蛋白H3K27M突变型弥漫性中线胶质瘤的临床病理特征及预后:30例分析
Zhonghua Bing Li Xue Za Zhi. 2019 Mar 8;48(3):192-198. doi: 10.3760/cma.j.issn.0529-5807.2019.03.005.
3
Diffuse midline glioma-H3K27M mutant. A novel entity with a defining and specific IHC marker.弥漫性中线胶质瘤-H3K27M突变型。一种具有明确且特异性免疫组化标志物的新实体。
Indian J Pathol Microbiol. 2021 Apr-Jun;64(2):351-353. doi: 10.4103/IJPM.IJPM_287_20.
4
Immunostaining of Increased Expression of Enhancer of Zeste Homolog 2 (EZH2) in Diffuse Midline Glioma H3K27M-Mutant Patients with Poor Survival.弥漫性中线胶质瘤 H3K27M 突变患者中 EZH2 表达增加与不良生存相关的免疫染色。
Pathobiology. 2019;86(2-3):152-161. doi: 10.1159/000496691. Epub 2019 May 16.
5
Detection of histone H3 K27M mutation and post-translational modifications in pediatric diffuse midline glioma via tissue immunohistochemistry informs diagnosis and clinical outcomes.通过组织免疫组化检测小儿弥漫性中线胶质瘤中的组蛋白H3 K27M突变和翻译后修饰可为诊断及临床预后提供依据。
Oncotarget. 2018 Dec 14;9(98):37112-37124. doi: 10.18632/oncotarget.26430.
6
Significance of H3K27M mutation with specific histomorphological features and associated molecular alterations in pediatric high-grade glial tumors.H3K27M突变在小儿高级别胶质瘤中具有特定组织形态学特征及相关分子改变的意义。
Childs Nerv Syst. 2018 Jan;34(1):107-116. doi: 10.1007/s00381-017-3633-5. Epub 2017 Oct 24.
7
Diffuse midline glioma H3K27M mutation in adult: A case report.成人弥漫性中线胶质瘤H3K27M突变:一例报告。
Ann Med Surg (Lond). 2022 Apr 4;76:103567. doi: 10.1016/j.amsu.2022.103567. eCollection 2022 Apr.
8
Significance of H3K27M Mutation in "Nonmidline" High-Grade Gliomas of Cerebral Hemispheres.H3K27M 突变在大脑半球“非中线”高级别胶质瘤中的意义。
World Neurosurg. 2019 Nov;131:174-176. doi: 10.1016/j.wneu.2019.08.024. Epub 2019 Aug 12.
9
Clinico-pathological and molecular characterization of diffuse midline gliomas: is there a prognostic significance?弥漫性中线胶质瘤的临床病理及分子特征:是否具有预后意义?
Neurol Sci. 2021 Mar;42(3):925-934. doi: 10.1007/s10072-020-04489-0. Epub 2020 Jul 14.
10
H3K27M Mutation Doesn't Mean Worse Prognosis in Old Patients.H3K27M突变并不意味着老年患者预后更差。
Front Oncol. 2022 Jun 8;12:912166. doi: 10.3389/fonc.2022.912166. eCollection 2022.

引用本文的文献

1
Initial Endoscopic Ventricular Failure to Relieve Hydrocephalus in Patients With Obstructing Brain Tumors Predicts a Histone 3K27M Mutation.梗阻性脑肿瘤患者初次内镜下脑室引流术未能缓解脑积水预示着组蛋白3K27M突变
Cureus. 2025 Feb 20;17(2):e79362. doi: 10.7759/cureus.79362. eCollection 2025 Feb.
2
Neuroradiological, genetic and clinical characteristics of histone H3 K27-mutant diffuse midline gliomas in the Kansai Molecular Diagnosis Network for CNS Tumors (Kansai Network): multicenter retrospective cohort.神经放射学、遗传学和中枢神经系统肿瘤关西分子诊断网络(Kansai Network)中组蛋白 H3 K27 突变型弥漫中线脑胶质瘤的临床特征:多中心回顾性队列研究。
Acta Neuropathol Commun. 2024 Jul 27;12(1):120. doi: 10.1186/s40478-024-01808-w.
3

本文引用的文献

1
Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas.影像学诊断的中线胶质瘤中 H3 K27M 突变的发生率及临床病理特征。
J Neurooncol. 2019 May;143(1):87-93. doi: 10.1007/s11060-019-03134-x. Epub 2019 Mar 12.
2
H3 K27M-mutant diffuse midline gliomas in different anatomical locations.不同解剖部位 H3 K27M 突变型弥漫中线胶质瘤。
Hum Pathol. 2018 Aug;78:89-96. doi: 10.1016/j.humpath.2018.04.015. Epub 2018 May 1.
3
Adult Brainstem Gliomas With H3K27M Mutation: Radiology, Pathology, and Prognosis.
The role of adjuvant chemotherapy in patients with H3K27 altered diffuse midline gliomas: a multicentric retrospective study.
H3K27 改变弥漫性中线脑胶质瘤患者辅助化疗的作用:一项多中心回顾性研究。
J Neurooncol. 2024 Mar;167(1):145-154. doi: 10.1007/s11060-024-04589-3. Epub 2024 Mar 8.
4
Aptamers in neuro-oncology: An emerging therapeutic modality.神经肿瘤学中的适体:一种新兴的治疗模式。
Neuro Oncol. 2024 Jan 5;26(1):38-54. doi: 10.1093/neuonc/noad156.
5
A validated prognostic nomogram for patients with H3 K27M-mutant diffuse midline glioma.用于 H3 K27M 突变型弥漫性中线胶质瘤患者的验证预后列线图。
Sci Rep. 2023 Jun 20;13(1):9970. doi: 10.1038/s41598-023-37078-0.
6
Systematic review of diffuse hemispheric glioma, H3 G34-mutant: Outcomes and associated clinical factors.弥漫性半球胶质瘤H3 G34突变型的系统评价:预后及相关临床因素
Neurooncol Adv. 2022 Aug 19;4(1):vdac133. doi: 10.1093/noajnl/vdac133. eCollection 2022 Jan-Dec.
7
Multiple subtentorial metastasis in diffuse midline glioma receiving tumor treating fields: a case report and literature review.接受肿瘤治疗电场的弥漫性中线胶质瘤幕下多发转移:一例报告及文献复习
Ann Transl Med. 2021 Oct;9(20):1604. doi: 10.21037/atm-21-4395.
伴有 H3K27M 突变的成人脑干胶质瘤:影像学、病理学和预后。
J Neuropathol Exp Neurol. 2018 Apr 1;77(4):302-311. doi: 10.1093/jnen/nly006.
4
H3 K27M-mutant gliomas in adults vs. children share similar histological features and adverse prognosis.成人与儿童的H3 K27M突变型胶质瘤具有相似的组织学特征和不良预后。
Clin Neuropathol. 2018 Mar/Apr;37 (2018)(2):53-63. doi: 10.5414/NP301085.
5
Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.弥漫性高级别胶质瘤伴 H3 K27M 突变无论肿瘤位置如何,预后均较差。
Neuro Oncol. 2018 Jan 10;20(1):123-131. doi: 10.1093/neuonc/nox149.
6
WHO 2016 Classification of gliomas.世界卫生组织 2016 年版《脑肿瘤分类》。
Neuropathol Appl Neurobiol. 2018 Feb;44(2):139-150. doi: 10.1111/nan.12432.
7
The 2016 WHO Classification of Tumours of the Central Nervous System: The Major Points of Revision.《2016年世界卫生组织中枢神经系统肿瘤分类:修订要点》
Neurol Med Chir (Tokyo). 2017 Jul 15;57(7):301-311. doi: 10.2176/nmc.ra.2017-0010. Epub 2017 Jun 8.
8
Characteristics of H3 K27M-mutant gliomas in adults.成人 H3 K27M 突变型神经胶质瘤的特征。
Neuro Oncol. 2017 Aug 1;19(8):1127-1134. doi: 10.1093/neuonc/now274.
9
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.2016 年世界卫生组织中枢神经系统肿瘤分类:概述。
Acta Neuropathol. 2016 Jun;131(6):803-20. doi: 10.1007/s00401-016-1545-1. Epub 2016 May 9.
10
Diffuse Midline Gliomas with Histone H3-K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations.伴组蛋白H3-K27M突变的弥漫性中线胶质瘤:47例病例系列研究,评估形态学变异谱及相关基因改变
Brain Pathol. 2016 Sep;26(5):569-80. doi: 10.1111/bpa.12336. Epub 2015 Dec 14.